Drugs / NX-5948
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT06717269 | Nov 2024 → Apr 2026 overdue | — | Nurix Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT06691828 | Nov 2024 | — | Nurix Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06593457 | Aug → Oct 2024 | — | Nurix Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05131022 | Apr 2022 → Jan 2027 expected | Waldenstrom macroglobulinemia, central nervous system non-hodgkin lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma +3 | Nurix Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07520006 | May 2026 → May 2033 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma | Nurix Therapeutics, Inc. | Not yet recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07221500 | Oct 2025 → Jan 2028 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma | Nurix Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07516093 | Jun 2026 → Oct 2029 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma | Nurix Therapeutics, Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NX-5948 | “NX-5948 oral” NCT06593457 ↗ |
| Known as | BTK-IN-24 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5558927 ↗ |
| Action | Inhibit | “NX-5948 is a BTK degrader and works by destroying the BTK protein to stop all its actions.” NCT07221500 ↗ |
| Modality | Other / unclassified | “a Bruton's Tyrosine Kinase (BTK) Degrader” NCT05131022 ↗ |
| Route | Oral | “Oral NX-5948” NCT05131022 ↗ |
| Target | BTK | “a Bruton's Tyrosine Kinase (BTK) Degrader” NCT05131022 ↗ |